risperidone has been researched along with Behavior Disorders in 192 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 9.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| "In this study we directly compared the efficacy and tolerability of the atypical antipsychotics quetiapine and risperidone in elderly patients with dementia and symptoms of disturbed perception, thought content, mood or behaviour (behavioural and psychological symptoms of dementia-BPSD)." | 9.12 | Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. ( Haushofer, M; Pfolz, H; Rainer, M; Struhal, C; Wick, W, 2007) |
| "Large randomized controlled trials have shown that risperidone reduces the frequency and severity of behavioral and psychological symptoms of dementia (BPSD) in patients with dementia." | 9.11 | Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. ( Wancata, J, 2004) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 9.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "To determine whether in utero exposure to the atypical antipsychotic risperidone is associated with poor pregnancy and fetal/neonatal outcomes." | 8.84 | Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. ( Coppola, D; Kwarta, RF; Russo, LJ; Schmider, J; Varughese, R, 2007) |
| "MEDLINE and EMBASE databases were used to identify controlled studies of risperidone in the treatment of disruptive behavior disorders and pervasive developmental disorders in pediatric patients, acute agitation or aggression in adults, and psychological and behavioral symptoms of dementia in the elderly." | 8.83 | Risperidone in the management of agitation and aggression associated with psychiatric disorders. ( Buitelaar, J; De Deyn, PP, 2006) |
| " The Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities comprised academic clinicians with at least 10 years' experience in the field of mental retardation and developmental disabilities." | 8.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| " After adjusting for age, there was no increased risk for breast cancer among risperidone users compared to patients exposed to another atypical antipsychotic (HR 0." | 7.85 | Risk of breast cancer in risperidone users: A nationwide cohort study. ( Bahmanyar, S; Brandt, L; Kieler, H; Qiu, H; Reutfors, J; Wang, Y; Wingård, L, 2017) |
| "Risperidone is the most widely used augmenting agent in the treatment of obsessive-compulsive disorder (OCD)." | 7.83 | Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India. ( Arumugham, SS; Hegde, A; Kalyani, BG; Math, SB; Narayanaswamy, JC; Reddy, YC, 2016) |
| "The atypical antipsychotic risperidone (RSP) is often associated with weight gain and cardiometabolic side effects." | 7.81 | Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. ( Azcarate-Peril, MA; Bahr, SM; Burns, TL; Butcher, BD; Calarge, CA; Kirby, JR; Oltman, CL; Teesch, LM; Tyler, BC; Wooldridge, N, 2015) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 7.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "We report a 5-case series in which risperidone use in usual or lower-than-usual doses was unexpectedly associated with amenorrhea." | 7.70 | Risperidone and associated amenorrhea: a report of 5 cases. ( Kim, L; Kim, YK; Lee, MS, 1999) |
| "Risperidone is a second-generation antipsychotic agent widely used in the treatment of schizophrenia and other psychotic disorders in adults." | 6.73 | Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ( Aman, MG; Lindsay, RL; Malone, K; Mannaert, E; Masty, J; Ramadan, Y; Remmerie, B; Vinks, AA, 2007) |
| "Dementia is associated with progressive cognitive impairment and behavioral and psychological symptoms." | 6.71 | Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. ( Diago, JI; Durán, JC; Gallego, R; Greenspan, A; Martinez, G, 2005) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 5.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "Average weight gain was significantly higher for the olanzapine group (mean = 4." | 5.34 | Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. ( Fleischhaker, C; Heiser, P; Hennighausen, K; Herpertz-Dahlmann, B; Holtkamp, K; Mehler-Wex, C; Rauh, R; Remschmidt, H; Schulz, E; Warnke, A, 2007) |
| "Data about their use in the treatment of enuresis also exist." | 5.32 | Reversible nocturnal enuresis in children receiving SSRI with or without risperidone: presentation of five cases. ( Aksu, HB; Kandil, ST; Ozyavuz, R, 2004) |
| "Risperidone was well tolerated overall and nursing staff viewed it as helpful in 38 of 100 patients, moderately helpful in 26, slightly helpful in 17, and not helpful in 19." | 5.30 | Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. ( Goldberg, J; Goldberg, RJ, 1997) |
| "Adverse changes in adiposity and insulin sensitivity were observed during 12 weeks of antipsychotic treatment in youths, with the greatest fat increases on olanzapine." | 5.27 | Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial. ( Flavin, KS; Newcomer, JW; Nicol, GE; Patterson, BW; Schechtman, KB; Schweiger, JA; Yingling, MD, 2018) |
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 5.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| " Aggression decreased substantially with all three treatments by 4 weeks, with the placebo group showing the greatest change (median decrease in MOAS score after 4 weeks=9 [95% CI 5-14] for placebo, 79% from baseline; 7 [4-14] for risperidone, 58% from baseline; 6." | 5.13 | Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. ( Ahmed, Z; Bhaumik, S; Bouras, N; Cooray, S; Crawford, M; Deb, S; Eliahoo, J; Hare, M; Harley, D; Karatela, S; Kramo, K; Meade, M; Murphy, D; North, B; Oliver-Africano, PC; Rao, B; Reece, B; Regan, A; Soni, A; Thomas, D; Tyrer, P, 2008) |
| "In this study we directly compared the efficacy and tolerability of the atypical antipsychotics quetiapine and risperidone in elderly patients with dementia and symptoms of disturbed perception, thought content, mood or behaviour (behavioural and psychological symptoms of dementia-BPSD)." | 5.12 | Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. ( Haushofer, M; Pfolz, H; Rainer, M; Struhal, C; Wick, W, 2007) |
| "Large randomized controlled trials have shown that risperidone reduces the frequency and severity of behavioral and psychological symptoms of dementia (BPSD) in patients with dementia." | 5.11 | Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. ( Wancata, J, 2004) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 5.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "Antipsychotics, particularly risperidone, appear to be effective in reducing problem behaviors in children with intellectual disability." | 4.93 | Pharmacotherapy for mental health problems in people with intellectual disability. ( Findling, RL; Ji, NY, 2016) |
| "To determine whether in utero exposure to the atypical antipsychotic risperidone is associated with poor pregnancy and fetal/neonatal outcomes." | 4.84 | Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. ( Coppola, D; Kwarta, RF; Russo, LJ; Schmider, J; Varughese, R, 2007) |
| "MEDLINE and EMBASE databases were used to identify controlled studies of risperidone in the treatment of disruptive behavior disorders and pervasive developmental disorders in pediatric patients, acute agitation or aggression in adults, and psychological and behavioral symptoms of dementia in the elderly." | 4.83 | Risperidone in the management of agitation and aggression associated with psychiatric disorders. ( Buitelaar, J; De Deyn, PP, 2006) |
| " There was a significant improvement in aggression with risperidone and olanzapine treatment compared to placebo." | 4.83 | The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. ( Ballard, C; Waite, J, 2006) |
| " The Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities comprised academic clinicians with at least 10 years' experience in the field of mental retardation and developmental disabilities." | 4.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| "To compare the efficacy and safety of risperidone and olanzapine in the treatment of psychotic symptoms and behavioural disturbances in institutionalised patients with dementia and other psychiatric disorders." | 4.82 | Atypical antipsychotics for nursing home patients: a retrospective chart review. ( Frenchman, IB, 2005) |
| "There is a now a substantial body of evidence that suggests the new antipsychotic agent, risperidone, may be safe and effective for treating psychotic, affective or behavioural symptoms associated with various disorders other than schizophrenia, schizophreniform disorder or schizo-affective disorder." | 4.81 | Does risperidone have a place in the treatment of nonschizophrenic patients? ( Schweitzer, I, 2001) |
| "The most convincing evidence of the efficacy of atypical neuroleptics in children and adolescents concerns clozapine in the treatment of schizophrenia." | 4.80 | Use of atypical neuroleptics in child and adolescent psychiatry. ( Laor, N; Toren, P; Weizman, A, 1998) |
| " The most often off-label prescribed drugs were quetiapine and mirtazapine for organic mental disorders (F0/G3), valproate and quetiapine in patients with disorders due to psychoactive substance use (F1), valproate in patients with psychotic disorders (F2), and risperidone and olanzapine in patients with affective disorders (F3)." | 4.12 | Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. ( Hefner, G; Klimke, A; Reißner, P; Toto, S; Wolff, J, 2022) |
| "Similar to older populations, risperidone treatment in preschoolers is associated with significant weight gain, with evidence for dose effects." | 4.02 | Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone. ( Avrahami, M; Balan-Moshe, L; Barzilay, R; Drapisz, A; Levy, T; Moore, T; Peskin, M; Segal-Gavish, H; Shachar, I; Taylor, J; Weizman, A, 2021) |
| " After adjusting for age, there was no increased risk for breast cancer among risperidone users compared to patients exposed to another atypical antipsychotic (HR 0." | 3.85 | Risk of breast cancer in risperidone users: A nationwide cohort study. ( Bahmanyar, S; Brandt, L; Kieler, H; Qiu, H; Reutfors, J; Wang, Y; Wingård, L, 2017) |
| "Risperidone is the most widely used augmenting agent in the treatment of obsessive-compulsive disorder (OCD)." | 3.83 | Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India. ( Arumugham, SS; Hegde, A; Kalyani, BG; Math, SB; Narayanaswamy, JC; Reddy, YC, 2016) |
| "The atypical antipsychotic risperidone (RSP) is often associated with weight gain and cardiometabolic side effects." | 3.81 | Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. ( Azcarate-Peril, MA; Bahr, SM; Burns, TL; Butcher, BD; Calarge, CA; Kirby, JR; Oltman, CL; Teesch, LM; Tyler, BC; Wooldridge, N, 2015) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| " The purpose of this study was to compare glucose homeostasis, insulin sensitivity, insulin secretion, and overall β-cell function in risperidone-treated, quetiapine-treated, and SGA-naive youth with mental illness." | 3.80 | Quetiapine treatment in youth is associated with decreased insulin secretion. ( Chanoine, JP; Davidson, J; Devlin, AM; Lynn, FC; Ngai, YF; Nguyen, D; Panagiotopoulos, C; Sabatini, P, 2014) |
| " The calorie-restricted diet was not significantly associated with a reduction in weight gain in participants who received any of the atypical antipsychotic agents except for olanzapine; therefore, findings indicate that the calorie-restricted diet may only be effective for patients receiving olanzapine." | 3.80 | The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications. ( Derbabian, B; Jacobowitz, W; Saunders, A, 2014) |
| "We report the case of a 16-year-old male with Mucopolysaccharidosis III type A (Sanfilippo syndrome) who was commenced on risperidone for behaviour management." | 3.75 | Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. ( Sillence, D; Tchan, MC, 2009) |
| "Parents of 101 children (age 5-17 years) with autism participating in a placebo-controlled trial of risperidone were given a questionnaire at the end of the study." | 3.73 | Research knowledge among parents of children participating in a randomized clinical trial. ( Aman, MG; Arnold, LE; Davies, M; McCracken, JT; McDougle, CJ; Scahill, L; Tierney, E; Vitiello, B, 2005) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 3.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "We report a 5-case series in which risperidone use in usual or lower-than-usual doses was unexpectedly associated with amenorrhea." | 3.70 | Risperidone and associated amenorrhea: a report of 5 cases. ( Kim, L; Kim, YK; Lee, MS, 1999) |
| " A case of 'PANDAS' is presented to increase physician awareness of this disorder and to document effectiveness of risperidone in chorea and treatment-resistant disruptive behavior associated with this syndrome." | 3.70 | Risperidone in the treatment of choreiform movements and aggressiveness in a child with "PANDAS". ( Bhatara, VS; Kleinsasser, BJ; Misra, LK; Sanchez, JD, 1999) |
| "Psychotic disorders are characterized by significant deficits in attentional control, but the neurobiological mechanisms underlying these deficits early in the course of illness prior to extensive pharmacotherapy are not well understood." | 2.79 | Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis. ( Gallego, JA; Gruner, P; Ikuta, T; John, M; Kane, J; Malhotra, AK; Peters, BD; Robinson, DG; Sevy, S; Szeszko, PR, 2014) |
| " The pharmacokinetic profile of risperidone is well documented in adults." | 2.75 | Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. ( Fabre, MA; Fuseau, E; Mannaert, E; Thyssen, A; Vermeulen, A, 2010) |
| "Risperidone (RIS) has the highest propensity to elevate plasma prolactin (PRL) levels." | 2.75 | Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients. ( Fukui, N; Inoue, Y; Ono, S; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J, 2010) |
| "Elderly patients with Alzheimer's disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects." | 2.74 | Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. ( Dagerman, KS; Hsiao, JK; Lebowitz, BD; Lyketsos, CG; Mack, WJ; Schneider, LS; Stroup, TS; Sultzer, DL; Tariot, PN; Vigen, C; Zheng, L, 2009) |
| "On risperidone treatment, the adjusted mean prolactin level at the 3rd month of treatment was significantly higher than at the 1st month; at the 12th month it was significantly lower than at the 1st month; the 1st and 6th months were not significantly different." | 2.74 | Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. ( D'Arrigo, C; de Leon, J; Diaz, FJ; Gagliano, A; Germanò, E; Migliardi, G; Siracusano, R; Spina, E, 2009) |
| " Patients were switched from their previous dosage of compressed tablets (0." | 2.73 | Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets. ( Binder, CE; Chue, P; Prinzo, RS, 2007) |
| "Risperidone is a second-generation antipsychotic agent widely used in the treatment of schizophrenia and other psychotic disorders in adults." | 2.73 | Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ( Aman, MG; Lindsay, RL; Malone, K; Mannaert, E; Masty, J; Ramadan, Y; Remmerie, B; Vinks, AA, 2007) |
| "Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies." | 2.72 | A crossover study of risperidone in children, adolescents and adults with mental retardation. ( Fleming, KK; Hellings, JA; Marquis, JG; Reese, RM; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2006) |
| " We used the Dosage Record Treatment Emergent Symptom Scale (DOTES) in a supplemented version to measure the presence and severity of side effects." | 2.72 | Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. ( Fleischhaker, C; Heiser, P; Hennighausen, K; Herpertz-Dahlmann, B; Holtkamp, K; Mehler-Wex, C; Rauh, R; Remschmidt, H; Schulz, E; Warnke, A, 2006) |
| "Risperidone treatment was generally well tolerated, although extrapyramidal symptoms were noted in a dose-dependent manner." | 2.71 | Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living. ( Choi, SK; Kim, JM; Lee, H; Shin, IS; Yoon, JS, 2003) |
| "promazine in the treatment of behavioral and psychological symptoms in dementia(BPSD)." | 2.71 | Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). ( Cotroneo, A; De Sarro, G; Gareri, P; Lacava, R; Loiacono, A; Marigliano, N; Seminara, G, 2004) |
| "Dementia is associated with progressive cognitive impairment and behavioral and psychological symptoms." | 2.71 | Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. ( Diago, JI; Durán, JC; Gallego, R; Greenspan, A; Martinez, G, 2005) |
| "Risperidone (1-8 mg/day) was associated with a 50 percent or greater reduction in at least one target behavior frequency in 61 percent of patients." | 2.68 | Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. ( Cohen, SA; Kerrick, JM; Lott, RS, 1996) |
| "Risperidone was significantly superior to placebo in its effect on the Aberrant Behaviour Checklist and the Clinical Global Impression." | 2.67 | Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. ( Buttiëns, M; Dierick, G; Geutjens, J; Heylen, S; Sieben, G; Thiry, P; Vanden Borre, R; Vermote, R, 1993) |
| "Hypothermia is unpredictable and life-threatening adverse effect of atypical antipsychotic drug (APD) treatment, which has been little described." | 2.61 | The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors. ( Araszkiewicz, AS; Szota, AM, 2019) |
| "Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone." | 2.58 | Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. ( Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T, 2018) |
| " It is well-tolerated and rather safe for elderly patients." | 2.48 | [Efficasy and safety of the use of risperidone (rispoluxe) in demented patients with psychotic and behavioural disorders]. ( Bocharov, AV; Kondakova, VE; Tuleninov, ES, 2012) |
| "Risperidone has been shown to be a safe and effective atypical antipsychotic agent." | 2.44 | Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. ( Bradbury, C; da Silva, TL; McKay, M; Ravindran, AV, 2007) |
| " This is because of their efficacy in the treatment of several psychiatric disorders, ease of administration, and absence of the well-known extrapyramidal adverse effects long-attributed to the standard dopamine blocking anti-psychotic medications." | 2.42 | Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. ( Bailey, RK, 2003) |
| "Risperidone was well tolerated in the elderly and associated with a low risk of movement disorders and anticholinergic effects." | 2.42 | Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. ( DeVane, CL; Mintzer, J, 2003) |
| "Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics." | 2.42 | The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. ( Citrome, L; Volavka, J, 2004) |
| "Despite the fact that psychiatric illness in the pre-adult era is not rare, few controlled clinical trials have examined the short-term safety and efficacy of these agents in youths with psychosis." | 2.39 | Antipsychotic medications in children and adolescents. ( Findling, RL; Grcevich, SJ; Lopez, I; Schulz, SC, 1996) |
| "Risperidone treatment in youth is associated with elevated appetite during an OGTT, with no differences in gut peptides or adipocytokines to explain risperidone's effect on appetite." | 1.48 | Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test: A Pilot Study. ( Devlin, AM; Ngai, YF; Panagiotopoulos, C, 2018) |
| " Groups were matched for demographic characteristics and daily dosage of RIS." | 1.46 | Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. ( Gründer, G; Haen, E; Hiemke, C; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Stegmann, B, 2017) |
| "Alterations of risperidone metabolism suggest pharmacokinetic interactions for levomepromazine and melperone." | 1.46 | Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. ( Gründer, G; Haen, E; Hiemke, C; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KRJ; Stegmann, B; Walther, S, 2017) |
| "The prevalence of hyperprolactinaemia in this population (n=67, 13%) was higher than in the general population." | 1.43 | Prolactin monitoring in the acute psychiatry setting. ( Goldring, KJ; Menon, SJ; Perry, BI, 2016) |
| " Despite lower dosing in patients >65 versus ≤65 years (median 1." | 1.43 | Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. ( Haslemo, T; Hoff, M; Molden, E; Waade, RB, 2016) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 1.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "Risperidone was prevalent in younger, male patients with disruptive behavioral disorders; aripiprazole, in patients with tic disorders." | 1.43 | Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison. ( Antoniazzi, S; Auricchio, F; Bernardini, R; Bertella, S; Bravaccio, C; Capuano, A; Carnovale, C; Cattaneo, D; Clementi, E; Ferrajolo, C; Gentili, M; Guastella, G; Mani, E; Molteni, M; Pascotto, A; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Riccio, MP; Rizzo, R; Rossi, F; Scuderi, MG; Sperandeo, S; Sportiello, L; Villa, L, 2016) |
| "Carbamazepine (CBZ) is an antiepileptic drug used as a mood stabilizer in child psychiatry." | 1.42 | [Carbamazepine and psychotropic treatment interaction: Two case studies of carbamazepine overdosage]. ( Askenazy, F; Dor, E; Fernandez, A; Menard, ML; Thümmler, S, 2015) |
| "Using a population pharmacokinetic approach, we aimed to characterize the genetic and non-genetic sources of variability affecting risperidone and 9-hydroxyrisperidone pharmacokinetics, and relate them to common side effects." | 1.42 | Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. ( Choong, E; Conus, P; Csajka, C; Eap, CB; Guidi, M; Vandenberghe, F; von Gunten, A, 2015) |
| " EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale." | 1.42 | Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. ( Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E, 2015) |
| "UHDRS (Unified Huntington's Disease Rating Scale) motor scores were obtained from medical records as an index of disease progression." | 1.42 | Examining Huntington's disease patient and informant concordance on frontally mediated behaviors. ( Cimino, CR; Hergert, DC; Sanchez-Ramos, J, 2015) |
| "The treatment with risperidone and aripiprazole in children with psychiatric disorders is not associated with clinically relevant modifications of QT interval." | 1.40 | ECG parameters in children and adolescents treated with aripiprazole and risperidone. ( Calabrò, MP; D'Amico, G; Gagliano, A; Germanò, E; Guerriero, L; Ingrassia, M; Italiano, D; Lamberti, M; Privitera, C; Siracusano, R; Spina, E, 2014) |
| " Risk assessment for the potential use of a drug, such as aripiprazole (Abilify), should not focus on any particular adverse effect, but rather should consider risk assessment in a broader context." | 1.40 | Atypical antipsychotics are not all alike: side effects and risk assessment. ( Howland, RH, 2014) |
| " Analysis of the ways in which the test results were reportedly utilized revealed that they generally played a supporting role with regard to dosing decisions, rather than being the main influence on clinician behaviour." | 1.38 | Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice. ( Butler, R; Dunbar, L; Miles, W; Pulford, J; Sheridan, J; Wheeler, A, 2012) |
| "The study aims were to characterize risperidone and (±)-9-hydroxyrisperidone pharmacokinetic (PK) variability in children and adolescents and to evaluate covariate effects on PK parameters." | 1.38 | Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. ( Aman, MG; Bies, RR; Saldaña, SN; Sherwin, CM; Vinks, AA, 2012) |
| "Risperidone LAT was typically used with recommended age and diagnostic groups." | 1.37 | Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. ( Becker, MA; Boaz, TL; Constantine, RJ; Howe, AM; Robst, J, 2011) |
| "Weight gain is an undesirable side effect of second-generation antipsychotics (SGAs)." | 1.37 | Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. ( Arango, C; Bretón, I; Camblor, M; Cuerda, C; de Castro, MJ; Desco, M; Dulín, E; García-Peris, P; Giráldez, M; Gutierrez, A; Leiva, M; Merchan-Naranjo, J; Parellada, M; Sanz, I; Velasco, C, 2011) |
| "The Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) was completed by 66 patients aged between 6 and 18 years who had been taking low-dose risperidone (alone or in conjunction with other medications) for up to 13 years." | 1.36 | Self-reported side effects in children and adolescents taking risperidone. ( Byrne, S; Cleary, M; Concannon, P; Crawford, G; Duffy, P; Hunt, G; Krabman, P; Malhi, G; Soh, N; Walter, G, 2010) |
| "Aripiprazole is a novel, third-generation antipsychotic with comparable efficacy to SGAs, but a more favorable side effect profile." | 1.36 | Aripiprazole as a viable alternative for treating delusions of parasitosis. ( Bhutani, T; Busse, KL; Koo, JY; Ladizinski, B, 2010) |
| " These long-term effects would not be captured by a standard 5-day pharmacokinetic TDM developmental testing model for antipsychotics, and a new model for characterizing variation in C/D by time course is therefore proposed." | 1.35 | Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. ( Darby, JK; Herbert, J; Pasta, DJ; Wilson, MG, 2008) |
| "Risperidone (N=45, 62%) was the most frequently prescribed antipsychotic drug, followed by olanzapine (24, 32%)." | 1.35 | Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. ( Alacqua, M; Arcoraci, V; Calarese, T; Di Vita, G; Gagliano, C; Germanò, E; Magazù, A; Spina, E; Trifirò, G, 2008) |
| "Citalopram was the most preferred antidepressant and Carbamazepine, the most preferred mood stabilizer/antiepileptic." | 1.35 | Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey. ( Deb, S; Unwin, GL, 2008) |
| "Treatment with risperidone solution orally or parenteral haloperidol until the day after admission, followed by olanzapine, successfully improved the clinical condition of the patients." | 1.35 | Three cases of schizophrenia for which olanzapine was effective after early acute phase. ( Inada, T; Oda, T; Yamamoto, N, 2008) |
| "Average weight gain was significantly higher for the olanzapine group (mean = 4." | 1.34 | Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. ( Fleischhaker, C; Heiser, P; Hennighausen, K; Herpertz-Dahlmann, B; Holtkamp, K; Mehler-Wex, C; Rauh, R; Remschmidt, H; Schulz, E; Warnke, A, 2007) |
| "Risperidone was the most frequently prescribed antipsychotic (n = 136, 44." | 1.33 | Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups. ( Curran, S; Musa, S; Turner, D; Wattis, J, 2005) |
| "The incidence of neuroleptic malignant syndrome (NMS) is not known, but the frequency of its occurrence with conventional antipsychotic agents has been reported to vary from 0." | 1.32 | Neuroleptic malignant syndrome and atypical antipsychotic drugs. ( Ananth, J; Burgoyne, K; Gunatilake, S; Parameswaran, S; Sidhom, T, 2004) |
| "Risperidone was highly effective and well tolerated in the treatment of behavioural disturbances in dementia under routine conditions of general practice." | 1.32 | [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients]. ( Delius-Stute, H; Kurz, A; Rettig, K; Schwalen, S, 2003) |
| "Data about their use in the treatment of enuresis also exist." | 1.32 | Reversible nocturnal enuresis in children receiving SSRI with or without risperidone: presentation of five cases. ( Aksu, HB; Kandil, ST; Ozyavuz, R, 2004) |
| "Family history of psychiatric illness and the presence of obstetric complications were estimated by a semistructured questionnaire." | 1.31 | Does risperidone act better in schizophrenic patients who have a family or obstetric history? ( Borkowska, A; Rybakowski, JK, 2002) |
| "Risperidone was well tolerated overall and nursing staff viewed it as helpful in 38 of 100 patients, moderately helpful in 26, slightly helpful in 17, and not helpful in 19." | 1.30 | Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. ( Goldberg, J; Goldberg, RJ, 1997) |
| "Risperidone was a useful adjunct in the treatment of agitation and psychosis in outpatients with dementia but was limited by EPS in about one-third of patients." | 1.30 | Risperidone treatment of behavioral disturbances in outpatients with dementia. ( Binetti, G; Ghaemi, SN; Gomez-Isla, T; Growdon, JH; Hyman, BT; Irizarry, MC; Lee-Cherry, ER, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 27 (14.06) | 18.2507 |
| 2000's | 94 (48.96) | 29.6817 |
| 2010's | 67 (34.90) | 24.3611 |
| 2020's | 4 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Hefner, G | 1 |
| Wolff, J | 1 |
| Toto, S | 1 |
| Reißner, P | 1 |
| Klimke, A | 1 |
| Semman, MF | 1 |
| Dadi, FG | 1 |
| Ijigu, GM | 1 |
| Moges, BT | 1 |
| Tesfaye, BT | 1 |
| Shen, SP | 1 |
| Liu, Y | 1 |
| Qiu, H | 2 |
| Tsai, KY | 1 |
| Wu, HC | 1 |
| Liang, WM | 1 |
| Shu, M | 1 |
| Chou, FH | 1 |
| John Jayakumar, JAK | 1 |
| Panicker, MM | 1 |
| Basu, B | 1 |
| Avrahami, M | 1 |
| Peskin, M | 1 |
| Moore, T | 1 |
| Drapisz, A | 1 |
| Taylor, J | 1 |
| Segal-Gavish, H | 1 |
| Balan-Moshe, L | 1 |
| Shachar, I | 1 |
| Levy, T | 1 |
| Weizman, A | 2 |
| Barzilay, R | 1 |
| Matera, E | 1 |
| Margari, L | 1 |
| Palmieri, VO | 1 |
| Zagaria, G | 1 |
| Palumbi, R | 1 |
| Margari, F | 1 |
| Hsu, CW | 1 |
| Lee, SY | 1 |
| Wang, LJ | 1 |
| Schoretsanitis, G | 4 |
| de Leon, J | 7 |
| Haen, E | 4 |
| Stegmann, B | 4 |
| Hiemke, C | 3 |
| Gründer, G | 4 |
| Paulzen, M | 4 |
| Temmingh, HS | 1 |
| Williams, T | 1 |
| Siegfried, N | 1 |
| Stein, DJ | 1 |
| Nesvåg, R | 1 |
| Bramness, JG | 1 |
| Handal, M | 1 |
| Hartz, I | 1 |
| Hjellvik, V | 1 |
| Skurtveit, S | 1 |
| Chopko, TC | 1 |
| Lindsley, CW | 1 |
| Perez-Cruzado, D | 1 |
| Cuesta-Vargas, A | 1 |
| Vera-Garcia, E | 1 |
| Mayoral-Cleries, F | 1 |
| Nicol, GE | 1 |
| Yingling, MD | 1 |
| Flavin, KS | 1 |
| Schweiger, JA | 1 |
| Patterson, BW | 1 |
| Schechtman, KB | 1 |
| Newcomer, JW | 1 |
| Dias Alves, M | 1 |
| Micoulaud-Franchi, JA | 1 |
| Simon, N | 1 |
| Vion-Dury, J | 1 |
| Lamy, M | 1 |
| Erickson, CA | 1 |
| Ngai, YF | 2 |
| Devlin, AM | 2 |
| Panagiotopoulos, C | 3 |
| Szota, AM | 1 |
| Araszkiewicz, AS | 1 |
| Buhagiar, K | 1 |
| Jabbar, F | 1 |
| Calarge, CA | 4 |
| Ziegler, EE | 1 |
| Najim, H | 1 |
| Islam, N | 1 |
| Ikuta, T | 1 |
| Robinson, DG | 1 |
| Gallego, JA | 1 |
| Peters, BD | 1 |
| Gruner, P | 1 |
| Kane, J | 1 |
| John, M | 1 |
| Sevy, S | 1 |
| Malhotra, AK | 1 |
| Szeszko, PR | 1 |
| Germanò, E | 3 |
| Italiano, D | 1 |
| Lamberti, M | 1 |
| Guerriero, L | 1 |
| Privitera, C | 1 |
| D'Amico, G | 1 |
| Siracusano, R | 2 |
| Ingrassia, M | 1 |
| Spina, E | 3 |
| Calabrò, MP | 1 |
| Gagliano, A | 2 |
| Sabatini, P | 1 |
| Nguyen, D | 2 |
| Davidson, J | 2 |
| Chanoine, JP | 1 |
| Lynn, FC | 1 |
| Jacobowitz, W | 1 |
| Derbabian, B | 1 |
| Saunders, A | 1 |
| Bachmann, CJ | 1 |
| Roessner, V | 1 |
| Glaeske, G | 1 |
| Hoffmann, F | 1 |
| Howland, RH | 1 |
| Citraro, R | 1 |
| Leo, A | 1 |
| Aiello, R | 1 |
| Pugliese, M | 1 |
| Russo, E | 1 |
| De Sarro, G | 2 |
| Arango, C | 3 |
| Giráldez, M | 3 |
| Merchán-Naranjo, J | 3 |
| Baeza, I | 2 |
| Castro-Fornieles, J | 1 |
| Alda, JA | 2 |
| Martínez-Cantarero, C | 2 |
| Moreno, C | 2 |
| de Andrés, P | 1 |
| Cuerda, C | 2 |
| de la Serna, E | 2 |
| Correll, CU | 2 |
| Fraguas, D | 1 |
| Parellada, M | 3 |
| Marston, L | 1 |
| Nazareth, I | 1 |
| Petersen, I | 1 |
| Walters, K | 1 |
| Osborn, DP | 1 |
| Connolly, JG | 1 |
| Toomey, TJ | 1 |
| Schneeweiss, MC | 1 |
| Fernandez, A | 1 |
| Dor, E | 1 |
| Menard, ML | 1 |
| Askenazy, F | 1 |
| Thümmler, S | 1 |
| Schlechte, JA | 1 |
| Burns, TL | 2 |
| Zemel, BS | 1 |
| Kulkarni, J | 1 |
| Storch, A | 1 |
| Baraniuk, A | 1 |
| Gilbert, H | 1 |
| Gavrilidis, E | 1 |
| Worsley, R | 1 |
| Vandenberghe, F | 1 |
| Guidi, M | 1 |
| Choong, E | 1 |
| von Gunten, A | 1 |
| Conus, P | 1 |
| Csajka, C | 1 |
| Eap, CB | 1 |
| Carbon, M | 1 |
| Kapoor, S | 1 |
| Sheridan, E | 1 |
| Al-Jadiri, A | 1 |
| Azzo, S | 1 |
| Sarkaria, T | 1 |
| Kane, JM | 1 |
| Saito, E | 1 |
| Hergert, DC | 1 |
| Sanchez-Ramos, J | 1 |
| Cimino, CR | 1 |
| Bahr, SM | 1 |
| Tyler, BC | 1 |
| Wooldridge, N | 1 |
| Butcher, BD | 1 |
| Teesch, LM | 1 |
| Oltman, CL | 1 |
| Azcarate-Peril, MA | 1 |
| Kirby, JR | 1 |
| Perry, BI | 1 |
| Goldring, KJ | 1 |
| Menon, SJ | 1 |
| Ronsley, R | 1 |
| Ji, NY | 1 |
| Findling, RL | 4 |
| Park, YM | 1 |
| Lee, SH | 1 |
| Lee, BH | 1 |
| Lee, KY | 1 |
| Lee, KS | 1 |
| Kang, SG | 1 |
| Lee, HY | 1 |
| Kim, W | 1 |
| Molden, E | 1 |
| Waade, RB | 1 |
| Hoff, M | 1 |
| Haslemo, T | 1 |
| Hegde, A | 1 |
| Kalyani, BG | 1 |
| Arumugham, SS | 1 |
| Narayanaswamy, JC | 1 |
| Math, SB | 1 |
| Reddy, YC | 1 |
| Lammertz, SE | 3 |
| Schruers, KR | 1 |
| Walther, S | 2 |
| An, FR | 1 |
| Yang, R | 1 |
| Wang, ZM | 1 |
| Ungvari, GS | 1 |
| Ng, CH | 1 |
| Chiu, HF | 1 |
| Wu, PP | 1 |
| Jin, X | 1 |
| Li, L | 1 |
| Lok, GK | 1 |
| Xiang, YT | 1 |
| Pozzi, M | 1 |
| Pisano, S | 1 |
| Bertella, S | 1 |
| Capuano, A | 1 |
| Rizzo, R | 1 |
| Antoniazzi, S | 1 |
| Auricchio, F | 1 |
| Carnovale, C | 1 |
| Cattaneo, D | 1 |
| Ferrajolo, C | 1 |
| Gentili, M | 1 |
| Guastella, G | 1 |
| Mani, E | 1 |
| Rafaniello, C | 1 |
| Riccio, MP | 1 |
| Scuderi, MG | 1 |
| Sperandeo, S | 1 |
| Sportiello, L | 1 |
| Villa, L | 1 |
| Radice, S | 1 |
| Clementi, E | 1 |
| Rossi, F | 1 |
| Pascotto, A | 1 |
| Bernardini, R | 1 |
| Molteni, M | 1 |
| Bravaccio, C | 1 |
| Reutfors, J | 1 |
| Wingård, L | 1 |
| Brandt, L | 1 |
| Wang, Y | 1 |
| Kieler, H | 1 |
| Bahmanyar, S | 1 |
| Schruers, KRJ | 1 |
| Darby, JK | 1 |
| Pasta, DJ | 1 |
| Wilson, MG | 1 |
| Herbert, J | 1 |
| Crespo-Facorro, B | 1 |
| Roiz-Santiáñez, R | 1 |
| Pérez-Iglesias, R | 1 |
| Pelayo-Terán, JM | 1 |
| Rodríguez-Sánchez, JM | 1 |
| Tordesillas-Gutiérrez, D | 1 |
| Ramírez, M | 1 |
| Martínez, O | 1 |
| Gutiérrez, A | 2 |
| de Lucas, EM | 1 |
| Vázquez-Barquero, JL | 1 |
| Jones, T | 1 |
| Van Breda, K | 1 |
| Charles, B | 1 |
| Dean, AJ | 1 |
| McDermott, BM | 1 |
| Norris, R | 1 |
| Zheng, L | 1 |
| Mack, WJ | 1 |
| Dagerman, KS | 2 |
| Hsiao, JK | 2 |
| Lebowitz, BD | 2 |
| Lyketsos, CG | 2 |
| Stroup, TS | 2 |
| Sultzer, DL | 2 |
| Tariot, PN | 3 |
| Vigen, C | 1 |
| Schneider, LS | 2 |
| Rodríguez-Antona, C | 1 |
| Gurwitz, D | 1 |
| Llerena, A | 1 |
| Kirchheiner, J | 1 |
| de Mesa, EG | 1 |
| Ibarreta, D | 1 |
| Romeo, R | 1 |
| Knapp, M | 1 |
| Tyrer, P | 2 |
| Crawford, M | 2 |
| Oliver-Africano, P | 1 |
| Tchan, MC | 1 |
| Sillence, D | 1 |
| Migliardi, G | 1 |
| D'Arrigo, C | 1 |
| Diaz, FJ | 1 |
| Dunbar, L | 1 |
| Butler, R | 1 |
| Wheeler, A | 4 |
| Pulford, J | 1 |
| Miles, W | 1 |
| Sheridan, J | 1 |
| Lapeire, LD | 1 |
| Tansens, A | 1 |
| Lemmens, GM | 1 |
| Van Belle, SJ | 1 |
| Sapunar Z, J | 1 |
| Muñoz N, S | 1 |
| Vásquez A, T | 1 |
| Pathak, P | 1 |
| West, D | 1 |
| Martin, BC | 1 |
| Helm, ME | 1 |
| Henderson, C | 1 |
| Byrne, S | 1 |
| Walter, G | 1 |
| Hunt, G | 1 |
| Soh, N | 1 |
| Cleary, M | 1 |
| Duffy, P | 1 |
| Crawford, G | 1 |
| Krabman, P | 1 |
| Concannon, P | 1 |
| Malhi, G | 1 |
| Moisan, J | 1 |
| Grégoire, JP | 1 |
| Alvarez, M | 1 |
| Sánchez, B | 1 |
| Thyssen, A | 1 |
| Vermeulen, A | 1 |
| Fuseau, E | 1 |
| Fabre, MA | 1 |
| Mannaert, E | 2 |
| Suzuki, Y | 1 |
| Fukui, N | 1 |
| Watanabe, J | 1 |
| Ono, S | 1 |
| Sugai, T | 1 |
| Tsuneyama, N | 1 |
| Inoue, Y | 1 |
| Someya, T | 1 |
| Boaz, TL | 1 |
| Constantine, RJ | 1 |
| Robst, J | 1 |
| Becker, MA | 1 |
| Howe, AM | 1 |
| Ladizinski, B | 1 |
| Busse, KL | 1 |
| Bhutani, T | 1 |
| Koo, JY | 1 |
| Miller, del D | 1 |
| Velasco, C | 1 |
| Leiva, M | 1 |
| de Castro, MJ | 1 |
| Bretón, I | 1 |
| Camblor, M | 1 |
| García-Peris, P | 1 |
| Dulín, E | 1 |
| Sanz, I | 1 |
| Desco, M | 1 |
| Hattori, K | 1 |
| Tanaka, H | 1 |
| Wakabayashi, C | 1 |
| Yamamoto, N | 2 |
| Uchiyama, H | 1 |
| Teraishi, T | 1 |
| Hori, H | 1 |
| Arima, K | 1 |
| Kunugi, H | 1 |
| Martínez-Ortega, JM | 1 |
| Diaz-Atienza, F | 1 |
| Gutiérrez-Rojas, L | 1 |
| Jurado, D | 1 |
| Gurpegui, M | 1 |
| Vanderpyl, J | 2 |
| Carswell, C | 2 |
| Stojkovic, M | 2 |
| Robinson, E | 2 |
| Koola, MM | 1 |
| Brown, WV | 1 |
| Qualls, C | 1 |
| Cuthbert, B | 1 |
| Hollis, JP | 1 |
| Kelly, DL | 1 |
| Le, NA | 1 |
| Raines, J | 1 |
| Duncan, EJ | 1 |
| Sherwin, CM | 1 |
| Saldaña, SN | 1 |
| Bies, RR | 1 |
| Aman, MG | 4 |
| Vinks, AA | 2 |
| Houston, JP | 1 |
| Kohler, J | 1 |
| Bishop, JR | 1 |
| Ellingrod, VL | 1 |
| Ostbye, KM | 1 |
| Zhao, F | 1 |
| Conley, RR | 1 |
| Poole Hoffmann, V | 1 |
| Fijal, BA | 1 |
| Bocharov, AV | 1 |
| Kondakova, VE | 1 |
| Tuleninov, ES | 1 |
| Bonci, G | 1 |
| Varghese, E | 1 |
| Mahgoub, N | 1 |
| Wilson, CA | 1 |
| Terry, AV | 1 |
| Onalaja, D | 1 |
| Jainer, AK | 1 |
| Borkowska, A | 1 |
| Rybakowski, JK | 1 |
| Levitas, A | 1 |
| Bailey, RK | 1 |
| Edell, WS | 1 |
| Rupnow, MF | 2 |
| Motsinger, CD | 1 |
| Perron, GA | 1 |
| Lacy, TJ | 1 |
| Timell, AM | 1 |
| Gabbay, V | 1 |
| Coffey, B | 1 |
| Kurz, A | 2 |
| Delius-Stute, H | 2 |
| Rettig, K | 2 |
| Schwalen, S | 2 |
| Valdovinos, MG | 2 |
| Zarcone, JR | 2 |
| Hellings, JA | 2 |
| Kim, G | 1 |
| Schroeder, SR | 2 |
| Kozyrev, VN | 1 |
| Smulevich, AB | 1 |
| Drobizhev, MIu | 1 |
| Kraeva, GK | 1 |
| Kubrakov, MA | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Yoon, JS | 1 |
| Kim, JM | 1 |
| Lee, H | 1 |
| Shin, IS | 1 |
| Choi, SK | 2 |
| McNamara, NK | 1 |
| Ananth, J | 2 |
| Parameswaran, S | 1 |
| Gunatilake, S | 1 |
| Burgoyne, K | 2 |
| Sidhom, T | 1 |
| DeVane, CL | 1 |
| Mintzer, J | 1 |
| Wancata, J | 2 |
| Gareri, P | 1 |
| Cotroneo, A | 1 |
| Lacava, R | 1 |
| Seminara, G | 1 |
| Marigliano, N | 1 |
| Loiacono, A | 1 |
| Zannino, G | 1 |
| Gargiulo, A | 1 |
| Lamenza, F | 1 |
| Marotta, MG | 1 |
| Barzotti, T | 1 |
| Silvestri, A | 1 |
| Ettorre, E | 1 |
| Marigliano, V | 1 |
| Cramer, JA | 1 |
| Sernyak, M | 1 |
| Profenno, LA | 1 |
| Ismail, MS | 2 |
| Ballard, CG | 1 |
| Margallo-Lana, ML | 1 |
| Gharabawi, GM | 1 |
| Rabinowitz, J | 2 |
| Katz, IR | 1 |
| De Deyn, PP | 3 |
| Brodaty, H | 2 |
| Greenspan, A | 2 |
| Davidson, M | 2 |
| Citrome, L | 1 |
| Volavka, J | 1 |
| Mukaddes, NM | 1 |
| Abali, O | 1 |
| Gurkan, K | 1 |
| Amdur, MA | 1 |
| Bobes, J | 1 |
| Cañas, F | 1 |
| Rejas, J | 1 |
| Mackell, J | 1 |
| Susce, MT | 2 |
| Pan, RM | 2 |
| Fairchild, M | 1 |
| Koch, WH | 2 |
| Wedlund, PJ | 3 |
| Vitiello, B | 1 |
| Scahill, L | 1 |
| McCracken, JT | 1 |
| McDougle, CJ | 1 |
| Tierney, E | 1 |
| Davies, M | 1 |
| Arnold, LE | 1 |
| Kandil, ST | 1 |
| Aksu, HB | 1 |
| Ozyavuz, R | 1 |
| Bryois, C | 1 |
| Nanzer, N | 1 |
| Eliez, S | 1 |
| Etter, M | 1 |
| Aubry, JM | 1 |
| Bertschy, G | 1 |
| Frenchman, IB | 1 |
| Miller, EA | 1 |
| Leslie, DL | 1 |
| Rosenheck, RA | 1 |
| Ballard, C | 2 |
| Cream, J | 1 |
| Shah, A | 2 |
| Suh, GH | 3 |
| Rapoport, M | 1 |
| Mamdani, M | 1 |
| Shulman, KI | 1 |
| Herrmann, N | 1 |
| Rochon, PA | 1 |
| Curran, S | 1 |
| Turner, D | 1 |
| Musa, S | 1 |
| Wattis, J | 1 |
| Durán, JC | 1 |
| Diago, JI | 1 |
| Gallego, R | 1 |
| Martinez, G | 1 |
| Katz, I | 1 |
| Cohen-Mansfield, J | 1 |
| Preskorn, SH | 1 |
| Pogge, DL | 1 |
| Singer, MB | 1 |
| Harvey, PD | 1 |
| Buitelaar, J | 1 |
| Waite, J | 1 |
| Reese, RM | 1 |
| Marquis, JG | 1 |
| Fleming, KK | 1 |
| Rondanelli, M | 1 |
| Sarra, S | 1 |
| Antoniello, N | 1 |
| Mansi, V | 1 |
| Govoni, S | 1 |
| Falvo, F | 1 |
| Solerte, SB | 1 |
| Ferrari, E | 1 |
| Fleischhaker, C | 2 |
| Heiser, P | 2 |
| Hennighausen, K | 2 |
| Herpertz-Dahlmann, B | 2 |
| Holtkamp, K | 2 |
| Mehler-Wex, C | 2 |
| Rauh, R | 2 |
| Remschmidt, H | 2 |
| Schulz, E | 2 |
| Warnke, A | 2 |
| Staller, J | 1 |
| Albanese, MJ | 1 |
| Suh, JJ | 1 |
| Lolk, A | 1 |
| Gulmann, NC | 1 |
| Davis, SM | 1 |
| Ryan, JM | 1 |
| Weintraub, D | 1 |
| Lieberman, JA | 1 |
| Ruaño, G | 1 |
| Goethe, JW | 1 |
| Caley, C | 1 |
| Woolley, S | 1 |
| Holford, TR | 1 |
| Kocherla, M | 1 |
| Windemuth, A | 1 |
| Kudo, T | 1 |
| Coppola, D | 1 |
| Russo, LJ | 1 |
| Kwarta, RF | 1 |
| Varughese, R | 1 |
| Schmider, J | 1 |
| Greenspan, AJ | 1 |
| Rainer, M | 1 |
| Haushofer, M | 1 |
| Pfolz, H | 1 |
| Struhal, C | 1 |
| Wick, W | 1 |
| Chue, P | 1 |
| Prinzo, RS | 1 |
| Binder, CE | 1 |
| Förstl, H | 1 |
| Yury, CA | 1 |
| Fisher, JE | 1 |
| Ito, T | 1 |
| Meguro, K | 1 |
| Akanuma, K | 1 |
| Meguro, M | 1 |
| Lee, E | 1 |
| Kasuya, M | 1 |
| Ishii, H | 1 |
| Mori, E | 1 |
| Alacqua, M | 1 |
| Trifirò, G | 1 |
| Arcoraci, V | 1 |
| Magazù, A | 1 |
| Calarese, T | 1 |
| Di Vita, G | 1 |
| Gagliano, C | 1 |
| Flanders, SC | 1 |
| Youngstrom, EA | 1 |
| Pandina, GJ | 1 |
| Jensik, SE | 1 |
| Carlson, GA | 1 |
| Bret, MC | 1 |
| Bret, P | 1 |
| Pariente, A | 1 |
| Fourier-Réglat, A | 1 |
| Ravindran, AV | 1 |
| Bradbury, C | 1 |
| McKay, M | 1 |
| da Silva, TL | 1 |
| Wooten, J | 1 |
| Remmerie, B | 1 |
| Ramadan, Y | 1 |
| Masty, J | 1 |
| Lindsay, RL | 1 |
| Malone, K | 1 |
| Gleason, MM | 1 |
| Egger, HL | 1 |
| Emslie, GJ | 1 |
| Greenhill, LL | 1 |
| Kowatch, RA | 1 |
| Lieberman, AF | 1 |
| Luby, JL | 1 |
| Owens, J | 1 |
| Scahill, LD | 1 |
| Scheeringa, MS | 1 |
| Stafford, B | 1 |
| Wise, B | 1 |
| Zeanah, CH | 1 |
| Barton, R | 1 |
| Unwin, GL | 1 |
| Deb, S | 2 |
| Oliver-Africano, PC | 1 |
| Ahmed, Z | 1 |
| Bouras, N | 1 |
| Cooray, S | 1 |
| Murphy, D | 1 |
| Hare, M | 1 |
| Meade, M | 1 |
| Reece, B | 1 |
| Kramo, K | 1 |
| Bhaumik, S | 1 |
| Harley, D | 1 |
| Regan, A | 1 |
| Thomas, D | 1 |
| Rao, B | 1 |
| North, B | 1 |
| Eliahoo, J | 1 |
| Karatela, S | 1 |
| Soni, A | 1 |
| Oda, T | 1 |
| Inada, T | 1 |
| Post, L | 1 |
| Johnstone, F | 1 |
| Rickard, I | 1 |
| Healy, D | 1 |
| Raheja, RK | 1 |
| Bharwani, I | 1 |
| Penetrante, AE | 1 |
| Klausner, M | 1 |
| Brecher, M | 1 |
| Vanden Borre, R | 1 |
| Vermote, R | 1 |
| Buttiëns, M | 1 |
| Thiry, P | 1 |
| Dierick, G | 1 |
| Geutjens, J | 1 |
| Sieben, G | 1 |
| Heylen, S | 1 |
| Grcevich, SJ | 1 |
| Lopez, I | 1 |
| Schulz, SC | 1 |
| Simon, EW | 1 |
| Blubaugh, KM | 1 |
| Pippidis, M | 1 |
| Lott, RS | 1 |
| Kerrick, JM | 1 |
| Cohen, SA | 1 |
| Goldberg, RJ | 1 |
| Goldberg, J | 1 |
| Zarate, CA | 1 |
| Baldessarini, RJ | 1 |
| Siegel, AJ | 1 |
| Nakamura, A | 1 |
| McDonald, J | 1 |
| Muir-Hutchinson, LA | 1 |
| Cherkerzian, T | 1 |
| Tohen, M | 1 |
| Toren, P | 1 |
| Laor, N | 1 |
| Balant-Gorgia, AE | 1 |
| Gex-Fabry, M | 1 |
| Genet, C | 1 |
| Balant, LP | 1 |
| Beers, MH | 1 |
| Nightengale, BS | 1 |
| Garrett, L | 1 |
| Waugh, S | 1 |
| Lawrence, BJ | 1 |
| Andrus, J | 1 |
| Meares, S | 1 |
| Draper, B | 1 |
| Buckley, PF | 1 |
| Kim, YK | 1 |
| Kim, L | 1 |
| Lee, MS | 1 |
| Jeste, DV | 1 |
| Lacro, JP | 1 |
| Bailey, A | 1 |
| Rockwell, E | 1 |
| Harris, MJ | 1 |
| Caligiuri, MP | 1 |
| Chengappa, KN | 1 |
| Sheth, S | 1 |
| Brar, JS | 1 |
| Parepally, H | 1 |
| Marcus, S | 1 |
| Gopalani, A | 1 |
| Palmer, A | 1 |
| Baker, RW | 1 |
| Schooler, NR | 1 |
| Irizarry, MC | 1 |
| Ghaemi, SN | 1 |
| Lee-Cherry, ER | 1 |
| Gomez-Isla, T | 1 |
| Binetti, G | 1 |
| Hyman, BT | 1 |
| Growdon, JH | 1 |
| Bork, JA | 1 |
| Rogers, T | 1 |
| Carroll, NB | 1 |
| Boehm, KE | 1 |
| Strickland, RT | 1 |
| Kleinsasser, BJ | 1 |
| Misra, LK | 1 |
| Bhatara, VS | 1 |
| Sanchez, JD | 1 |
| Hammond, CM | 1 |
| Pierson, JF | 1 |
| Grande, TP | 1 |
| Munetz, MR | 1 |
| Wilson, DR | 1 |
| Pathak, DS | 1 |
| Aquino, S | 1 |
| Coley, KC | 1 |
| Carter, CS | 1 |
| DaPos, SV | 1 |
| Maxwell, R | 1 |
| Wilson, JW | 1 |
| Branch, RA | 1 |
| Reynolds, PL | 1 |
| Strayer, SM | 1 |
| Moretti, M | 1 |
| Varga, G | 1 |
| Schweitzer, I | 1 |
| Belzie, LR | 1 |
| Wirshing, WC | 1 |
| Simeon, J | 1 |
| Milin, R | 1 |
| Walker, S | 1 |
| Ratzoni, G | 1 |
| Gothelf, D | 1 |
| Brand-Gothelf, A | 1 |
| Reidman, J | 1 |
| Kikinzon, L | 1 |
| Gal, G | 1 |
| Phillip, M | 1 |
| Apter, A | 1 |
| Weizman, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroimaging Biomarker-Guided Personalized Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Major Depressive Episode in Adolescents and Young Adults With Mood Disorders: A Randomized, Double-Blind, Controlled Study[NCT05465928] | 120 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| Metabolic Effects of Antipsychotics in Children[NCT00205699] | Phase 4 | 144 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| CYP2D6 PHARMACOGENETICS IN RISPERIDONE-TREATED CHILDREN AND ADOLESCENTS WITH PSYCHIATRIC OR NEURODEVELOPMENTAL DISORDERS[NCT00783783] | 47 participants (Actual) | Observational | 2008-11-30 | Completed | |||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo[NCT00088036] | Phase 3 | 450 participants | Interventional | 2004-02-29 | Completed | ||
| Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549] | Phase 4 | 500 participants | Interventional | 2004-10-31 | Completed | ||
| The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321] | Phase 3 | 600 participants | Interventional | 2002-04-30 | Completed | ||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo[NCT00091650] | Phase 3 | 300 participants | Interventional | 2004-03-31 | Completed | ||
| A Pragmatic Randomized-controlled Trial of a Multi-pronged Electronic Health Record-based Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions Among Older Adults With Alzheimer's and Related Dementias[NCT04851691] | 117 participants (Anticipated) | Interventional | 2021-08-03 | Enrolling by invitation | |||
| Elderly Patients With Dementia in the Department of Acute Geriatrics: Pilot Study, Monocentric, Randomized Use of Aromatherapy as a Complementary Treatment to Psychopharmacotherapy in Psychological Disorders and BPSD Behavior[NCT03662360] | 32 participants (Actual) | Interventional | 2018-05-20 | Completed | |||
| DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics[NCT00752960] | 1,000 participants (Anticipated) | Observational | 2007-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This study hypothesized that antipsychotic treatment would increase percent total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | percent body fat (Mean) |
|---|---|
| Risperidone | 1.81 |
| Olanzapine | 4.12 |
| Aripiprazole | 1.66 |
This study hypothesized that antipsychotic treatment would decrease hepatic insulin sensitivity, as measured by the rate of appearance of glucose (glucose Ra), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | percentage of % change (Mean) |
|---|---|
| Risperidone | -2.50 |
| Olanzapine | -6.57 |
| Aripiprazole | -3.27 |
This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at muscle, as measured by the insulin-stimulated rate of disappearance of glucose (glucose Rd), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | percentage of % change (Mean) |
|---|---|
| Risperidone | 2.30 |
| Olanzapine | -29.34 |
| Aripiprazole | -30.26 |
This study hypothesized that antipsychotic treatment would decrease insulin sensitivity at adipose tissue, as measured by the insulin-stimulated rate of disappearance of glycerol (glycerol Ra), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | percentage of % change (Mean) |
|---|---|
| Risperidone | -3.65 |
| Olanzapine | -8.29 |
| Aripiprazole | 1.70 |
This study hypothesized that antipsychotic treatment would increase subcutaneous abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | Change in cm-squared (Mean) |
|---|---|
| Risperidone | 18.21 |
| Olanzapine | 34.27 |
| Aripiprazole | 15.84 |
This study hypothesized that antipsychotic treatment would increase visceral abdominal fat, as measured by abdominal magnetic resonance imaging (MRI), with larger adverse effects for olanzapine. (NCT00205699)
Timeframe: 12 weeks
| Intervention | Change in cm-squared (Mean) |
|---|---|
| Risperidone | 6.85 |
| Olanzapine | 10.73 |
| Aripiprazole | 12.04 |
"The Neuropsychiatric Inventory - Nursing Home Version (NPI-NH) test will characterize the neuropsychiatric and psychopathological symptoms of patients affected by dementia.~Events as delirium, anxiety, depression, etc. will be recorded by the frequency (from 0, absence, to 4, high frequency) and the seriousness (from 0, absence, to 3, high). The total score of the NPI-NH is given by the frequency x (multiply) seriousness (total score for each event has a range from 0 to 12). The patient final score will be given by the sum of the score of the 12 events. For each patient will be given a total score from 0 to 144.~NPI NH score has been collected in both control and aromatherapy groups at T1 and T3, in patients who needed and who did not needed Pro Re Nata." (NCT03662360)
Timeframe: Time 1 (baseline) and Time 3 (day 7)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| T1 NPI score in patients do not need Pro Re Nata | T3 NPI score in patients needed Pro Re Nata | T3 NPI score in patients do not need Pro Re Nata | |
| GROUP A - Control Group | 21.81 | 32.87 | 20.00 |
| GROUP B - Aromatherapy Group | 25.93 | 16.5 | 7.25 |
NPI-NH assess the psychological distress in physicians, nurses and nursing assistants who managed the patients. It has a score from 0 (no discomfort) to score of 5 (extreme discomfort). The psychological distress is measured for each of the 12 events in the NPI-NH scale, for a total score from 0 to 60. (NCT03662360)
Timeframe: Time 1 (baseline) and Time 3 (day 7)
| Intervention | score on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 NPI NH physicians in pts with PRN | T1 NPI NH physicians in pts without PRN | T1 NPI NH nurses in pts with PRN | T1 NPI NH nurses in pts without PRN | T1 NPI NH nursing assistants in pts with PRN | T1 NPI NH nursing assistants in pts without PRN | T3 NPI NH physician in pts with PRN | T3 NPI NH physician in pts without PRN | T3 NPI NH nurses in pts with PRN | T3 NPI NH nurses in pts without PRN | T3 NPI NH nursing assistants in pts with PRN | T3 NPI NH nursing assistants in pts without PRN | |
| GROUP A - Control Group | 4.19 | 1.60 | 9.63 | 6.40 | 11.00 | 7.10 | 6.00 | 3.20 | 12.00 | 9.30 | 13.19 | 9.90 |
| GROUP B - Aromatherapy Group | 5.64 | 4.13 | 11.64 | 10.13 | 12.21 | 10.88 | 2.64 | 0.88 | 5.79 | 4.25 | 5.93 | 4.38 |
35 reviews available for risperidone and Behavior Disorders
| Article | Year |
|---|---|
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disor | 2018 |
Classics in Chemical Neuroscience: Risperidone.
Topics: Animals; Humans; Mental Disorders; Risperidone; Serotonin Antagonists | 2018 |
Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders.
Topics: Adolescent; Aripiprazole; Autism Spectrum Disorder; Child; Comorbidity; Guidelines as Topic; Humans; | 2018 |
The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.
Topics: Antipsychotic Agents; Humans; Hypothermia; Mental Disorders; Olanzapine; Risk Factors; Risperidone; | 2019 |
Association of First- vs. Second-Generation Antipsychotics with Lipid Abnormalities in Individuals with Severe Mental Illness: A Systematic Review and Meta-Analysis.
Topics: Antipsychotic Agents; Clozapine; Humans; Lipids; Mental Disorders; Olanzapine; Risperidone | 2019 |
Antipsychotic use in pregnancy.
Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Huma | 2015 |
Pharmacotherapy for mental health problems in people with intellectual disability.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Ce | 2016 |
[Risk of type 2 diabetes mellitus among users of atypical antipsychotic drugs or conventional treatment: systematic review and meta-analysis].
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Diabetes Mellitus, Type 2; Humans; Mental Disorder | 2009 |
[Efficasy and safety of the use of risperidone (rispoluxe) in demented patients with psychotic and behavioural disorders].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition; Dementia; Female; Humans; Male; Mental Dis | 2012 |
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.
Topics: Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Black or African American; | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; | 2004 |
Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update.
Topics: Aged; Antipsychotic Agents; Humans; Mental Disorders; Neurodegenerative Diseases; Risperidone | 2003 |
Efficacy of atypical antipsychotics in elderly patients with dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric | 2004 |
The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities.
Topics: Aged; Antipsychotic Agents; Choice Behavior; Controlled Clinical Trials as Topic; Dementia; Dibenzot | 2004 |
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
Topics: Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Basal Ganglia Dise | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzoth | 2004 |
[Psychiatry].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperacti | 2005 |
Atypical antipsychotics for nursing home patients: a retrospective chart review.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Homes for the Aged; Humans; Medical Records; | 2005 |
Risperidone in the management of agitation and aggression associated with psychiatric disorders.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Humans; Menta | 2006 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepin | 2006 |
[Psychopharmacological treatment of behavioral and psychological symptoms in dementia].
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; | 2006 |
[Application of neuroleptics for dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Dementia; Diben | 2007 |
Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Induced; Abortion, Spontaneous; Adult; Antipsychotic Agents; | 2007 |
Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.
Topics: Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazep | 2007 |
Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders.
Topics: Animals; Anxiety Disorders; Depressive Disorder; Humans; Mental Disorders; Risperidone | 2007 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepine | 2007 |
Psychopharmacological treatment for very young children: contexts and guidelines.
Topics: Algorithms; Amphetamines; Antidepressive Agents; Antipsychotic Agents; Atomoxetine Hydrochloride; At | 2007 |
Use of medication in children with psychiatric disorders.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; D | 2007 |
Antipsychotic medications in children and adolescents.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Cl | 1996 |
Use of atypical neuroleptics in child and adolescent psychiatry.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Child Development Diso | 1998 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
Does risperidone have a place in the treatment of nonschizophrenic patients?
Topics: Bipolar Disorder; Clinical Trials as Topic; Dementia; Humans; Mental Disorders; Obsessive-Compulsive | 2001 |
Movement disorders associated with neuroleptic treatment.
Topics: Age Factors; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; | 2001 |
A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Child; Humans; Ment | 2002 |
28 trials available for risperidone and Behavior Disorders
| Article | Year |
|---|---|
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.
Topics: Abdominal Fat; Absorptiometry, Photon; Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug-R | 2018 |
Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis.
Topics: Adult; Aged; Antipsychotic Agents; Attention; Basal Ganglia; Brain; Double-Blind Method; Female; Glo | 2014 |
Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brain; Double-Blind Method; Fema | 2008 |
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2009 |
The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.
Topics: Adult; Aggression; Antipsychotic Agents; Combined Modality Therapy; Cost-Benefit Analysis; Double-Bl | 2009 |
Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Drug Adm | 2009 |
Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Child; Female; Hum | 2010 |
Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients.
Topics: Adult; Aged; Chromatography, Liquid; Enzyme-Linked Immunosorbent Assay; Female; Humans; Isoxazoles; | 2010 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Using the Diagnostic Assessment of the Severely Handicapped-II (DASH-II) to measure the therapeutic effects of risperidone.
Topics: Antipsychotic Agents; Cross-Over Studies; Disabled Persons; Double-Blind Method; Humans; Mental Diso | 2004 |
Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Cognition; Dose-Response | 2003 |
Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Mental Disorders; Middle Aged; Prospective Studies; Ri | 2004 |
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Brain; Diagnostic | 2004 |
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Female; Hum | 2004 |
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up St | 2004 |
Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Female; Humans; Mal | 2005 |
A crossover study of risperidone in children, adolescents and adults with mental retardation.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Studies; D | 2006 |
Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics.
Topics: Adolescent; Adolescent Psychiatry; Adult; Antipsychotic Agents; Benzodiazepines; Child; Child Psychi | 2006 |
The effect of long-term antipsychotic treatment on prolactin.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cross-Sectional Studies; | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Apolipoprote | 2007 |
Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Dibenzothiazepines; Female; Humans; Male; M | 2007 |
Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Female; Humans; Male; Mental Disorders; Mid | 2007 |
Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.
Topics: Adolescent; Antipsychotic Agents; Area Under Curve; Child; Child, Preschool; Cytochrome P-450 CYP2D6 | 2007 |
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
Topics: Adult; Aged; Aggression; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Mental Competency; | 2008 |
Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Therapy, | 1993 |
Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance.
Topics: Adult; Aged; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Prognosis | 1996 |
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonist | 1999 |
129 other studies available for risperidone and Behavior Disorders
| Article | Year |
|---|---|
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Humans; Male; Mental Disorders | 2022 |
Management practice and discharge outcome of patients with psychiatric disorder admitted to psychiatry wards of selected specialized settings in Ethiopia.
Topics: Adult; Cross-Sectional Studies; Diazepam; Ethiopia; Hospitals, Psychiatric; Humans; Mental Disorders | 2023 |
The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Case-Control Studies; Female; Femo | 2019 |
Serotonin 2A (5-HT
Topics: Amphetamines; Animals; Antipsychotic Agents; Cell-Matrix Junctions; Chlorpromazine; HEK293 Cells; Hu | 2020 |
Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone.
Topics: Age Factors; Antipsychotic Agents; Body Mass Index; Child, Preschool; Dose-Response Relationship, Dr | 2021 |
Risperidone and Cardiometabolic Risk in Children and Adolescents: Clinical and Instrumental Issues.
Topics: Adolescent; Antipsychotic Agents; Cardiovascular Diseases; Child; Child, Preschool; Female; Follow-U | 2017 |
Response to "Risperidone and sulpiride: Brands vs generics".
Topics: Antipsychotic Agents; Drugs, Generic; Humans; Mental Disorders; Risperidone; Sulpiride | 2018 |
Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Acti | 2018 |
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Dis | 2018 |
Medication and physical activity and physical fitness in severe mental illness.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Exercise; Female; Humans; Male; Mental Disorde | 2018 |
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Cloz | 2018 |
Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test: A Pilot Study.
Topics: Adolescent; Antipsychotic Agents; Appetite; Child; Cross-Sectional Studies; Female; Humans; Male; Me | 2018 |
Iron deficiency in pediatric patients in long-term risperidone treatment.
Topics: Adolescent; Antipsychotic Agents; Central Nervous System Stimulants; Child; Cross-Sectional Studies; | 2013 |
Checking physical care of people on risperidone long term injectable depot.
Topics: Adolescent; Adult; Antipsychotic Agents; Comorbidity; Delayed-Action Preparations; Female; Health St | 2013 |
ECG parameters in children and adolescents treated with aripiprazole and risperidone.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Electrocardiography; Female | 2014 |
Quetiapine treatment in youth is associated with decreased insulin secretion.
Topics: Adolescent; Animals; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Cross-Sectional St | 2014 |
The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Caloric Restriction; Education, Nursing, | 2014 |
Trends in psychopharmacologic treatment of tic disorders in children and adolescents in Germany.
Topics: Adolescent; Adolescent Psychiatry; Antipsychotic Agents; Child; Child Psychiatry; Drug Prescriptions | 2015 |
Atypical antipsychotics are not all alike: side effects and risk assessment.
Topics: Antipsychotic Agents; Aripiprazole; Decision Making; Humans; Mental Disorders; Off-Label Use; Patien | 2014 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epi | 2015 |
Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Child; Child, Preschool; Co | 2014 |
Prescribing of antipsychotics in UK primary care: a cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Child; Cohort St | 2014 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; B | 2015 |
[Carbamazepine and psychotropic treatment interaction: Two case studies of carbamazepine overdosage].
Topics: Adolescent; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Drug Overdose; Drug | 2015 |
The effect of psychostimulants on skeletal health in boys co-treated with risperidone.
Topics: Absorptiometry, Photon; Adolescent; Bone and Bones; Child; Child, Preschool; Cross-Sectional Studies | 2015 |
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Cytochrome P-450 CYP2D6; Female; Humans; Longi | 2015 |
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dru | 2015 |
Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
Topics: Adult; Aged; Antipsychotic Agents; Awareness; Cognition Disorders; Disease Progression; Female; Fron | 2015 |
Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children.
Topics: Adolescent; Antipsychotic Agents; Bacteroidetes; Child; Cross-Sectional Studies; Female; Firmicutes; | 2015 |
Prolactin monitoring in the acute psychiatry setting.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Male; Mental Diso | 2016 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
Topics: Adult; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Male; Mental Disorders; Middle Aged | 2016 |
Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Alleles; Antipsychotic Agents; Cytoc | 2016 |
Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
Topics: Adult; Aftercare; Antipsychotic Agents; Comorbidity; Drug Synergism; Female; Humans; India; Male; Me | 2016 |
Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antipsychotic Agent | 2016 |
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Case-Control Studies; China; Cloza | 2016 |
Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2016 |
Risk of breast cancer in risperidone users: A nationwide cohort study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antipsychotic Agents; Breast Neoplasms | 2017 |
Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome | 2017 |
Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics.
Topics: Adult; Antipsychotic Agents; Databases, Pharmaceutical; Drug Monitoring; Drug Synergism; Drug Therap | 2017 |
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antipsychotic Agents; Benzodiazepines; Biotransformation | 2008 |
Determination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders.
Topics: Adolescent; Antipsychotic Agents; Child; Chromatography, High Pressure Liquid; Female; Humans; Isoxa | 2009 |
CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Cytochrome P-450 CYP2D6; Genetic Testing; Genotype; Ger | 2009 |
Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.
Topics: Adolescent; Adult; Anticonvulsants; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; C | 2009 |
Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice.
Topics: Antipsychotic Agents; Attitude of Health Personnel; Biotransformation; Community Mental Health Cente | 2012 |
Carcinoid encephalopathy: A single entity or a spectrum of different disorders?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoid Tumor; Combined Mo | 2010 |
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Clozapine; | 2010 |
Self-reported side effects in children and adolescents taking risperidone.
Topics: Adolescent; Antipsychotic Agents; Child; Cross-Sectional Studies; Female; Humans; Male; Mental Disor | 2010 |
Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Topics: Adult; Age Distribution; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Databases | 2010 |
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Biomarkers; Bipolar Disorder; Body Mass Index; Ch | 2010 |
Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Comorbidity; Delayed-Action Pre | 2011 |
Aripiprazole as a viable alternative for treating delusions of parasitosis.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Mental Disorders; | 2010 |
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Topics: Adolescent; Aging; Antipsychotic Agents; Body Mass Index; Child; Child Development Disorders, Pervas | 2011 |
Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics.
Topics: Adiponectin; Adolescent; Adolescent Development; Antipsychotic Agents; Basal Metabolism; Benzodiazep | 2011 |
Expression of Ca²⁺-dependent activator protein for secretion 2 is increased in the brains of schizophrenic patients.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Autopsy; Brain; Calcium-Binding Proteins; Cerebral Corte | 2011 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disrupti | 2011 |
Explicit review of risperidone long-acting injection prescribing practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cross-Sectional Studies; Delayed-A | 2011 |
Reduced arterial compliance in patients with psychiatric diagnoses.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Blood Pressure; Compliance; Dibenzothiazepi | 2012 |
One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Delayed-Action Preparations; Drug Adm | 2012 |
Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Cohort Studies; Cytochrome P-450 CYP2D6; | 2012 |
A case of Diogenes syndrome: clinical and ethical challenges.
Topics: Aged, 80 and over; Antihypertensive Agents; Antipsychotic Agents; Diagnosis, Differential; Female; G | 2012 |
Variable maternal stress in rats alters locomotor activity, social behavior, and recognition memory in the adult offspring.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Atomoxetine Hydrochloride; | 2013 |
Re: Chan et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16: 1156 - 1162.
Topics: Alzheimer Disease; Antipsychotic Agents; China; Double-Blind Method; Haloperidol; Humans; Mental Dis | 2002 |
Does risperidone act better in schizophrenic patients who have a family or obstetric history?
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Female; Humans; Male; Me | 2002 |
Reader response to, "Effects of risperidone on aberrant behavior in persons with developmental disabilities: I. A double-blind crossover study using multiple measures".
Topics: Antipsychotic Agents; Cross-Over Studies; Double-Blind Method; Humans; Intellectual Disability; Ment | 2003 |
Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cost Savings; Dib | 2003 |
Use of atypical antipsychotic drugs in patients with dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Dementia; Dibenzothiazepines; H | 2003 |
Re: Thioridazine: re-evaluating the risk/benefit equation.
Topics: Antipsychotic Agents; Data Collection; Death, Sudden; Electrocardiography; Female; Humans; Long QT S | 2003 |
Obsessive-Compulsive disorder, Tourette's disorder, or pediatric autoimmune neuropsychiatric disorders associated with Streptococcus in an adolescent? Diagnostic and therapeutic challenges.
Topics: Adolescent; Antipsychotic Agents; Autoimmune Diseases; Citalopram; Clinical Laboratory Techniques; D | 2003 |
[Treatment of behavioral disorders in dementia with risperidone in psychogeriatric outpatients].
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dementia; Follow-Up Studies; Humans; Mental Disorder | 2003 |
[Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepin | 2003 |
Neuroleptic malignant syndrome and atypical antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bromocriptine; Clozapine; Dantrolene; Dibenzothi | 2004 |
The management of psychogeriatric patient.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Ag | 2004 |
Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate.
Topics: Adolescent; Adult; Age Factors; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Dibenzothia | 2004 |
[Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Butyrophenones; C | 2003 |
Short-term efficacy and safety of risperidone in young children with autistic disorder (AD).
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Diagnostic and Statist | 2004 |
Impractical features of long-acting risperidone.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy; Humans; Mental Disorders; Risperido | 2004 |
The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 CYP2D6; Dose-Response Relation | 2005 |
Research knowledge among parents of children participating in a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Attitude to Health; Autistic Disorder; Child; Child, Preschool; Co | 2005 |
Cerebrovascular events after treatment of dementia patients with risperidone.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Female; Humans; Ischemic Attack, Transient; | 2004 |
Reversible nocturnal enuresis in children receiving SSRI with or without risperidone: presentation of five cases.
Topics: Adolescent; Antipsychotic Agents; Child; Drug Therapy; Drug Therapy, Combination; Enuresis; Female; | 2004 |
[Facilitating nursing at home and in the nursing home].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Clinical Trials as Topic; Consensus Development Confe | 2005 |
Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Fema | 2005 |
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.
Topics: Accidental Falls; Aged; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cognition; | 2005 |
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Geriatric Psychiatry; Humans; Ischemic Attack | 2005 |
Antipsychotic use in the elderly: shifting trends and increasing costs.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Drug Costs | 2005 |
Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents | 2005 |
Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
Topics: Adult; Aged; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochro | 2005 |
Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Confidence Intervals; Dementia, Va | 2005 |
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studie | 2005 |
Drug-drug interactions: Proof of relevance (Part II): cause of tolerability problems or noncompliance.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 E | 2005 |
Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Mental Disorders; Olanzapin | 2005 |
No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Di | 2006 |
Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; | 2006 |
Risperidone in cocaine-dependent patients with comorbid psychiatric disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Cocaine-Related Disorders; Comorbidity; Counseling; Diagnos | 2006 |
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Clozapine; Female; Humans; Ma | 2007 |
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Haloper | 2007 |
[Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2007 |
Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Cognition Dis | 2007 |
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Citalopram; Drug Ut | 2008 |
Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Child; Child, Pre | 2007 |
The use of atypical antipsychotics in French psychiatric hospitals.
Topics: Adult; Age Factors; Amisulpride; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents; Benzo | 2007 |
Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey.
Topics: Adult; Aggression; Antipsychotic Agents; Attitude of Health Personnel; Autistic Disorder; Carbamazep | 2008 |
Three cases of schizophrenia for which olanzapine was effective after early acute phase.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Foll | 2008 |
Risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Community Mental Health Services; Humans; Isoxazoles; Menta | 1994 |
The costs of psychotropic medication.
Topics: Antipsychotic Agents; Budgets; Clozapine; Costs and Cost Analysis; Drug Monitoring; Humans; Mental D | 1995 |
Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation.
Topics: Aged; Antipsychotic Agents; Clonazepam; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1995 |
Risperidone guidelines.
Topics: Antipsychotic Agents; Clozapine; Guidelines as Topic; Humans; Mental Disorders; Patient Selection; R | 1995 |
Substituting traditional antipsychotics with risperidone for individuals with mental retardation.
Topics: Adult; Aged; Antipsychotic Agents; Comorbidity; Dose-Response Relationship, Drug; Dyskinesia, Drug-I | 1996 |
Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Resistance; Female; Geriatric Assessme | 1997 |
Risperidone in the elderly: a pharmacoepidemiologic study.
Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity; | 1997 |
Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders. Part I: Unique patient populations.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Humans; Mental D | 1998 |
Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Chromatography, High Pressure Liq | 1999 |
Risperdal advertising in JAGS. Journal of the American Geriatrics Society.
Topics: Advertising; Aged; Antipsychotic Agents; Dementia; Drug Industry; Humans; Mental Disorders; Patient | 1999 |
Economic outcomes associated with the use of risperidone in a naturalistic group practice setting.
Topics: Antipsychotic Agents; Cohort Studies; Group Practice; Humans; Mental Disorders; Outcome Assessment, | 1998 |
Treatment of vocally disruptive behaviour of multifactorial aetiology.
Topics: Aged; Akathisia, Drug-Induced; Behavior Therapy; Dementia; Depression; Female; Homes for the Aged; H | 1999 |
Risperidone and associated amenorrhea: a report of 5 cases.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Bipolar Disorder; Female; Follow-Up Studies; Humans; Mental | 1999 |
Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.
Topics: Aged; Antipsychotic Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Haloperidol; | 1999 |
Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Dementia; Drug Admin | 1999 |
Risperidone treatment of behavioral disturbances in outpatients with dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Re | 1999 |
A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Topics: Adolescent; Adult; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Cytoch | 1999 |
Chorea and tardive dyskinesia in a patient taking risperidone.
Topics: Adolescent; Aggression; Antipsychotic Agents; Chorea; Dyskinesia, Drug-Induced; Female; Humans; Ment | 1999 |
Risperidone in the treatment of choreiform movements and aggressiveness in a child with "PANDAS".
Topics: Aggression; Antipsychotic Agents; Autoimmune Diseases; Child; Child Behavior Disorders; Chorea; Huma | 1999 |
Economic evaluation of risperidone in an outpatient population.
Topics: Ambulatory Care; Antipsychotic Agents; Female; Hospitals, Psychiatric; Humans; Male; Mental Disorder | 1999 |
Meige's syndrome associated with risperidone therapy.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Male; Meige Syndrome; Mental Di | 2000 |
Neuroleptics for behavioral symptoms of dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Evidence-Based Medicine; Humans; Mental Disorders; Resea | 2000 |
[Psychosomatic dermatologic symptoms].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Diagnosis, Differential; Female; Humans; Mental Disor | 2000 |
Risperidone for AIDS-associated dementia: a case series.
Topics: Adult; AIDS Dementia Complex; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Mental | 1996 |
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Mental Disorde | 2002 |